Neu Health Ltd. received $2 million in funding from Cedars-Sinai Intellectual Property Company and Oxford Science Enterprises (OSE) to bring its platform, designed for Parkinson’s disease and dementia care, into the U.S.
The EU has moved aggressively on legislation in recent years, with the AI Liability Directive serving as the latest example of legislation that sparked widespread opposition.
The final tally shows U.K. biotechs raised £3.5 billion (US$4.35 billion) in 2024, a stonking 93% more than in 2023, and surpassing the total in 2020, before the life sciences investment boom sparked by the pandemic. Of this, £2.1 billion was in venture capital, a 64.8% increase on 2023, while U.K biotechs attracted £1.5 billion in follow-on offerings, most of it raised by companies listed on Nasdaq.
Nobi BV secured €35 million (US$37 million) in an oversubscribed series B financing round to develop its artificial intelligence (AI)-powered smartlights which can detect falls in the elderly.
Harness Therapeutics Ltd. has raised fresh financing to further develop its technology for upregulating the translation of mRNA into proteins, and in particular to take on a previously undruggable target in Huntington’s disease.
Harness Therapeutics Ltd. has raised fresh financing to further develop its technology for upregulating the translation of mRNA into proteins, and in particular to take on a previously undruggable target in Huntington’s disease.
A new bioprinting platform to create tissues that can change shape as a result of forces generated by the cells, similar to what happens naturally during organ development, was developed by researchers from the University of Galway, Ireland.
Newco Linkgevity Ltd. has won backing from the KQ Labs accelerator program at the Francis Crick Institute in London, enabling it to take forward the lead program, an anti-necrotic drug for treating acute kidney injury, and to further develop its AI-driven system for identifying aging-related therapeutic targets. Alongside access to the Crick’s expertise in translational research and in shaping academic science to make it investible, companies joining KQ Labs receive an equity investment.
Inflammatory diseases specialist AB2 Bio Ltd. has signed a potential $686 million U.S. commercialization deal for its interleukin-18 neutralizing drug tadekinig. The agreement with Japanese pharma company Nippon Shinyaku Co. Ltd. includes an initial payment of $6 million, with a further $30 million due later this year.
The U.K.’s new postmarket monitoring requirements do not represent a sea change in device makers’ responsibilities in this area, but the expansions of responsibility are nonetheless significant.
RSS
